- Continued resurgence from Big Pharma in the top 10, most new approvals now from biotech
LONDON, April 2, 2019 /PRNewswire/ -- The ninth annual Pharmaceutical Innovation Index, released by IDEA Pharma today, sees Gilead top the industry for the first time.
The Pharmaceutical Innovation Index measures, scores and celebrates a company's ability to deliver innovation to patients, by objectively evaluating performance based on a rolling five year period (2013-2018), and operates on the simple premise: if you gave the same molecule to two different companies in early phase, which would make the best of it?
Gilead have risen consistently, by one place per year since 2016, to the top of the table, with an outstanding antiviral performance - in 2018, Gilead derived 60% of its revenues from new drugs, more than twice any other company, and 6 times more than the average across the top 30. The biggest riser this year is Eli Lilly, rising 10 places on a strong performance across the board. Similarly, Sanofi have gained nine places, year on year, while Pfizer's 2018 saw them gain more approvals than any other company.
Pharmaceutical Innovation Index 2019
1 2 +1
2 5 +3
3 13 +10
4 9 +5
5 7 +2
Merck & Co.
6 15 +9
7 10 +3
8 8 +0
9 3 -6
10 13 +3
In a year that showed a record number of new drug approvals at the FDA, it is notable that over half were for rare diseases, and 39 of the 59 FDA approvals went to small- to mid-sized biotech (companies outside of the top 30), suggesting that there are significant innovation and productivity challenges for large pharma in the coming years.
Commenting on the index, IDEA Pharma's CEO, Mike Rea said: "There is no gaming the Pharmaceutical Innovation Index - success is achieved by discovering and developing meaningfully great medicines and getting those medicines to market, and to patients. What Gilead has achieved is remarkable - they have redefined success for this industry - launching truly meaningful medicines, and embracing novelty and originality over incrementalism. The Index also shows that successful innovation is not evenly distributed - more than half of the top 30 companies did not achieve an approval in 2018, suggesting strong headwinds for those pharma companies who've not embraced the new era."
For a more in-depth look at this year's Pharmaceutical Innovation Index, details of the methodology and the top 30 companies, visit http://www.ideapharma.com/pii [http://www.ideapharma.com/pii]
Photo: https://mma.prnewswire.com/media/843535/Pharmas_most_innovative_companies__2019.jpg [https://mma.prnewswire.com/media/843535/Pharmas_most_innovative_companies__2019.jpg]
For more information please contact:
Sam Varney Communications Director IDEA Pharma Tel: +44-1234-756-340 Email: firstname.lastname@example.org [mailto:email@example.com]
Web site: http://www.ideapharma.com//